Stephen K. Doberstein

2017

In 2017, Stephen K. Doberstein earned a total compensation of $7.7M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 347% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$525,000
Option Awards$3,672,084
Salary$529,084
Stock Awards$2,958,794
Other$13,988
Total$7,698,950

Doberstein received $3.7M in option awards, accounting for 47.70% of the total pay in 2017.

Doberstein also received $525K in non-equity incentive plan, $529.1K in salary, $3M in stock awards and $14K in other compensation.

Rankings

In 2017, Stephen K. Doberstein's compensation ranked 958th out of 13,916 executive pay records tracked by us. In other words, Doberstein earned more than 93.1% of all executives tracked by us in 2017.

ClassificationRankingPercentile
All
958
out of 13,916
93rd
Manufacturing
Division
330
out of 5,489
94th
Chemicals And Allied Products
Major group
85
out of 1,934
96th
Drugs
Industry group
56
out of 1,601
97th
Pharmaceutical Preparations
Industry
48
out of 1,231
96th
Source: SEC filing on April 30, 2018.

Doberstein's colleagues

We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2017.

2017

Howard Robin

Nektar Therapeutics

Chief Executive Officer

2017

John Nicholson

Nektar Therapeutics

Chief Operating Officer

2017

Gil Labrucherie

Nektar Therapeutics

Chief Financial Officer

2017

Maninder Hora

Nektar Therapeutics

Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer

News

You may also like